Progress and challenges in dengue vaccine development
10.3760/cma.j.cn112309-20230912-00072
- VernacularTitle:登革热疫苗研究进展与挑战
- Author:
Yiming SUN
1
;
Huiqiang YANG
;
Yonghong GE
Author Information
1. 中国药科大学生命科学与技术学院，南京 210000
- Keywords:
Dengue virus;
Dengue fever vaccine;
Antibody-dependent enhancement;
Non-structural protein
- From:
Chinese Journal of Microbiology and Immunology
2024;44(7):635-640
- CountryChina
- Language:Chinese
-
Abstract:
Dengue fever, caused by of dengue virus (DENV) infection, is one of the most prevalent arboviral infections worldwide. It is estimated that approximately 390 million people are infected with DENV each year, of whom approximately 96 million will develop clinical symptoms and one in every twenty people may develop severe dengue leading to shock, internal bleeding and death. DENV includes four serotypes (1-4), each of which can cause various forms of disease. There is currently no specific treatment for dengue fever, and only two vaccines have been approved for use in some countries: CYD-TDV and TAK-003. CYD-TDV, which is suitable for people aged 9-45, can be affected by antibody-dependent enhancement (ADE), leading to more severe infections. Therefore, how to reduce or eliminate ADE becomes an important issue in current dengue vaccine research. In addition, the effects of DENV non-structural proteins on the immune system cannot be ignored. Currently, at least seven dengue vaccines are in various stages of development and clinical trials. This review will focus on three vaccine candidates that have made significant progress, and summarize the ways to avoid ADE the progress in the development of dengue vaccines using non-structural proteins as immunogens.
